Dr. Albert Bourla, Chairman and CEO of Pfizer, has spearheaded the company’s mission of “Breakthroughs that change patients’ lives” through scientific and commercial innovation.” With over 30 years at Pfizer, Bourla has held senior positions globally, enriching his understanding of diverse healthcare needs. Taking on the CEO role in 2019, he reoriented Pfizer towards a science-driven model, increasing R&D investments and digital innovations. Bourla’s leadership was crucial during the COVID-19 pandemic, where Pfizer developed a vaccine in eight months without public funding and later introduced the first FDA-authorized oral antiviral treatment for COVID-19. His book, "Moonshot," details this journey.
Under Bourla’s guidance, Pfizer has also emphasized environmental, social, and governance (ESG) principles, launching its first ESG report and the biopharmaceutical industry's first Sustainability Bond. Bourla also possesses a PhD in biotechnology of reproduction and a doctorate of veterinary medicine. His leadership extends to multiple boards and organizations, reflecting his broad influence in the pharmaceutical industry and beyond. Bourla's strategic vision and dedication to equitable access to healthcare continue to drive Pfizer's transformative impact on global health.